Hongjian Li

Title: Innovations of Hongjian Li in Biopharmaceuticals

Introduction

Hongjian Li is a prominent inventor based in Shenzhen, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative therapies targeting cancer. With a focus on single domain antibodies, his work has the potential to revolutionize treatment options for patients.

Latest Patents

Hongjian Li holds 2 patents that showcase his expertise and innovative spirit. His latest patents include "Anti-BCMA single domain antibodies and application thereof," which describes a group of anti-BCMA single domain antibodies, their genes, and various applications in detection and treatment. These antibodies are characterized by high activity, stability, specificity, and binding capability. Another notable patent is "BCMA chimeric antigen receptor based on single domain antibody and use thereof," which details a chimeric antigen receptor (CAR) that includes a BCMA binding domain and various functional domains essential for its activity.

Career Highlights

Hongjian Li is currently associated with Shenzhen Pregene Biopharma Co. Ltd., where he continues to push the boundaries of biopharmaceutical research. His work is instrumental in developing therapies that could significantly improve patient outcomes in oncology.

Collaborations

He collaborates with talented individuals such as Jishuai Zhang and ChaoLemeng Bao, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Hongjian Li's contributions to the field of biopharmaceuticals through his patents and collaborative efforts highlight his role as a leading inventor. His work promises to advance cancer treatment and improve the lives of many patients.